ライフサイエンスコーパス: bypass surgery

1 = 11) before and after weight loss (gastric bypass surgery).

2 ry revascularization (800,000 PCI vs 350,000 bypass surgeries).

3 ar all-cause mortality after coronary artery bypass surgery.

4 anagement intervention and Roux-en-Y gastric bypass surgery.

5 glucose and lipid homeostasis after duodenal bypass surgery.

6 aortic aneurysm repair, and lower extremity bypass surgery.

7 patients undergoing elective coronary artery bypass surgery.

8 onse of bariatric patients following gastric bypass surgery.

9 cebo for 2 to 6 weeks before coronary artery bypass surgery.

10 ternal mammary artery of patients undergoing bypass surgery.

11 more than 5 years following coronary artery bypass surgery.

12 usion in patients undergoing coronary artery bypass surgery.

13 idence of in-hospital mortality or emergency bypass surgery.

14 biopsy samples were obtained during coronary bypass surgery.

15 occur in patients undergoing cardiopulmonary bypass surgery.

16 ery with traditional on-pump coronary artery bypass surgery.

17 n great saphenous veins harvested at cardiac bypass surgery.

18 reatment of depression after coronary artery bypass surgery.

19 mal weight, morbidly obese, and post-gastric-bypass surgery.

20 of long-term survival after coronary artery bypass surgery.

21 to cardiac ischemia, such as during coronary bypass surgery.

22 d weight loss benefits observed post-gastric bypass surgery.

23 measures plus survival) for coronary artery bypass surgery.

24 e considered equivalent, if not superior, to bypass surgery.

25 e considered equivalent, if not superior, to bypass surgery.

26 ed operative mortality after coronary artery bypass surgery.

27 linemic hypoglycemia after Roux-en-Y gastric bypass surgery.

28 72%) patients had a previous coronary artery bypass surgery.

29 ive coronary arteries, and often necessitate bypass surgery.

30 epeat percutaneous coronary intervention and bypass surgery.

31 recurrence to less than 5%, rivaling that of bypass surgery.

32 tive anatomy and complications after gastric bypass surgery.

33 mic inflammatory response to cardiopulmonary bypass surgery.

34 it to combining ventricular restoration with bypass surgery.

35 e should not be a deterrent for recommending bypass surgery.

36 48 hours after the onset of cardiopulmonary bypass surgery.

37 oscopic off-pump multivessel coronary artery bypass surgery.

38 isk of complications or death after coronary bypass surgery.

39 tally endoscopic approach to coronary artery bypass surgery.

40 ium-201 ((201)Tl) tomography before coronary bypass surgery.

41 ischemic ventricular dysfunction undergoing bypass surgery.

42 diabetic patients undergoing coronary artery bypass surgery.

43 32% had prior PCI and 19% had prior coronary bypass surgery.

44 omplete revascularization in coronary artery bypass surgery.

45 ed with an echocardiogram three months after bypass surgery.

46 spirin could improve survival after coronary bypass surgery.

47 disease who were undergoing coronary artery bypass surgery.

48 +/- 6.3 kg/m(2); 46 +/- 11 y) during gastric-bypass surgery.

49 n resistance associated with cardiopulmonary bypass surgery.

50 ars) weight loss following Roux-en-Y gastric bypass surgery.

51 litus and patients following cardiopulmonary bypass surgery.

52 s coronary intervention, and coronary artery bypass surgery.

53 n resistance/diabetes after gastrointestinal bypass surgery.

54 enefit of BIMA up to 10 years after coronary bypass surgery.

55 in CSCs isolated from 38 patients undergoing bypass surgery.

56 reflecting the vascular growth needed before bypass surgery.

57 apid antidiabetic effect of duodenal jejunal bypass surgery.

58 ing to the control of diabetes after gastric bypass surgery.

59 ous complications after laparoscopic gastric bypass surgery.

60 patients undergoing a priori coronary artery bypass surgery.

61 ic deterioration and decreased after gastric bypass surgery.

62 ed tunnel endoscopic harvesting for coronary bypass surgery.

63 ity or major morbidity after coronary artery bypass surgery.

64 on of gut hormones following certain gastric bypass surgeries.

65 coronary intervention, 32%; coronary artery bypass surgery, 10%).

66 tained from 386 patients undergoing coronary bypass surgery (127 with type 2 diabetes).

67 angioplasty (34.6% vs. 22.6%; p < 0.001), or bypass surgery (14.1% vs. 10.4%; p < 0.001) but had a si

68 7.1% vs 20.0%, P < .001) and coronary artery bypass surgery (2.7% vs 4.2%, P < .01).

69 y intervention (28%), urgent coronary artery bypass surgery (27.5%), maternal mortality (4%), and fet

70 ial infarction (MI) (2%) and coronary artery bypass surgery (3%).

71 d survived and not undergone coronary artery bypass surgery 30 days after discharge were followed up

72 ysm repair (51% vs 38%), and lower extremity bypass surgery (32% vs 3%).

73 Of 591 patients undergoing cardiopulmonary bypass surgery, 57 (9.6%) tested positive for anti-prota

74 coronary intervention, 38%; coronary artery bypass surgery, 7%).

75 (32.1% versus 23.8%; P<0.001), and coronary bypass surgery (9.2% versus 5.7%; P<0.001).

76 xcluding patients with prior coronary artery bypass surgery, 925 patients were included in the analys

77 Although gastric bypass surgery accounts for 80% of bariatric surgery in

78 tion (adjusted HR, 0.26; 95% CI, 0.13-0.54), bypass surgery (adjusted HR, 0.47; 95% CI, 0.30-0.73), o

79 in 53 patients who were undergoing coronary bypass surgery (age 60+/-11 years; 13% female).

80 rcutaneous coronary intervention and reduced bypass surgery along with improved clinical outcomes ove

81 rn after maternal bariatric gastrointestinal bypass surgery (AMS) are less obese and exhibit improved

82 erall, 6 of 168 patients had coronary artery bypass surgery and 33 of 168 had percutaneous coronary i

83 A cohort of 7925 patients undergoing gastric bypass surgery and 7925 group-matched, severely obese in

84 mong 9949 patients who had undergone gastric bypass surgery and 9628 severely obese persons who appli

85 etes mellitus-1 managed by Roux-en-Y gastric bypass surgery and a comparable group managed medically.

86 nd restenosis limit the long-term utility of bypass surgery and angioplasty due to pathological proli

87 domized revascularization candidates between bypass surgery and angioplasty.

88 the peri-infarct area has been performed at bypass surgery and by subendocardial injection in the ca

89 er our understanding of SVG remodeling after bypass surgery and may guide future research to help pre

90 ment on progression of atherosclerosis after bypass surgery and on risk of IHD in the second Northwic

91 Both coronary artery bypass surgery and percutaneous intervention have been u

92 dysfunction underwent MCE 1 to 5 days before bypass surgery and repeat echocardiography at 3 to 4 mon

93 n usage within the 5 days preceding coronary bypass surgery and risk of adverse in-hospital postopera

94 farction, urgent or emergent coronary artery bypass surgery and stroke) and to construct a simple sco

95 Off-pump coronary bypass surgery and the newest generation of drug-eluting

96 wo other deaths occurred, one after coronary bypass surgery and the other from hepatic failure.

97 ale sex (P= 0.028), whereas history of prior bypass surgery and use of stents resulted in a decreased

98 al infarction, and emergency coronary artery bypass surgery) and follow-up survival were compared bet

99 ans of percutaneous coronary intervention or bypass surgery) and to receive the best available medica

100 ous coronary angioplasty, or coronary artery bypass surgery) and total mortality (CHD, cardiovascular

101 aphenous vein graft occlusion after coronary bypass surgery), and particularly those with diabetes, u

102 atients, 13% had PCI, 2% had coronary artery bypass surgery, and 3% died during the readmission.

103 tal cohort of individuals undergoing gastric bypass surgery, and DMGV levels fell in parallel with im

104 llation, diabetes mellitus, previous cardiac bypass surgery, and higher implanter procedural volume w

105 vels of endogenous GLP-1 occur after gastric bypass surgery, and mechanistic studies indicate glucose

106 cannulated RAs as grafts in coronary artery bypass surgery, and there are no clear guidelines on the

107 We included eligible PCI, coronary artery bypass surgery, and valve surgery patients from 2010 to

108 litation referral after PCI, coronary artery bypass surgery, and valve surgery.

109 ntervention (angioplasty, or coronary artery bypass surgery), angina and/or unspecified ischaemic hea

110 ar disease, absence of prior coronary artery bypass surgery, angina, low body mass index (<21 kg/m(2)

111 n via percutaneous interventions or coronary bypass surgery are appropriate in specific cases or when

112 Patients undergoing isolated coronary artery bypass surgery at 2 hospitals were divided into derivati

113 2 whites undergoing isolated coronary artery bypass surgery at 663 Society of Thoracic Surgery Databa

114 ortality benefit in those undergoing gastric bypass surgery at ages younger than 35 years primarily d

115 SD BMI 54.7 +/- 12.6 kg/m(2)) during gastric bypass surgery at Barnes-Jewish Hospital.

116 The need for bypass surgery at one year was reduced among patients ra

117 dergoing first-time isolated coronary artery bypass surgery at our institution from January 2000 thro

118 ,067 consecutive patients undergoing gastric bypass surgery at the UCLA Medical Center from December

119 or full service centers with coronary artery bypass surgery available.

120 ty, Minnesota, who underwent coronary artery bypass surgery between 1996 and 2007.

121 identified 6376 patients undergoing gastric bypass surgery between 2006 and 2008.

122 type 2 diabetes mellitus undergoing gastric bypass surgery between January 2000 and July 2004, 78 pa

123 cts were studied before and after intestinal bypass surgery (biliopancreatic diversion [BPD]).

124 ith lower mortality rates in coronary artery bypass surgery, but how volume and quality of care relat

125 cularization by 21% and reduced the need for bypass surgery by 44%.

126 patients undergoing elective coronary artery bypass surgery (CABG) after cardiac catheterization.

127 Coronary bypass surgery (CABG) and angioplasty (PTCA) have been c

128 ondary preventive medications after coronary bypass surgery (CABG) and percutaneous coronary interven

129 The choice between coronary artery bypass surgery (CABG) and percutaneous coronary interven

130 Coronary artery bypass surgery (CABG) and percutaneous coronary interven

131 e completion angiogram after coronary artery bypass surgery (CABG) and simultaneous (1-stop) percutan

132 However, emergency coronary artery bypass surgery (CABG) for failed PCI is still associated

133 ations for optimal timing of coronary artery bypass surgery (CABG) in patients with non-ST-segment-el

134 erformed in conjunction with coronary artery bypass surgery (CABG) in the United States for asymptoma

135 d the incidence of AKI after coronary artery bypass surgery (CABG) or after percutaneous coronary int

136 determinant of early or late coronary artery bypass surgery (CABG) outcomes.

137 ous vein grafts to the aorta during coronary bypass surgery (CABG) without cross-clamping.

138 be stimulated at the time of coronary artery bypass surgery (CABG), and if dissection of this FP decr

139 xclusively in the setting of coronary artery bypass surgery (CABG), and no study has repeated delayed

140 ogistic regression modeling, coronary artery bypass surgery (CABG), either isolated or combined with

141 ality in patients undergoing coronary artery bypass surgery (CABG).

142 or late mortality following coronary artery bypass surgery (CABG).

143 idity in patients undergoing coronary artery bypass surgery (CABG).

144 ients with ISR who underwent coronary artery bypass surgery (CABG).

145 vention (PCI) With Taxus and coronary artery bypass surgery (CABG)] score is a decision-making tool i

146 Mortality after coronary-artery bypass surgery (CABS) has fallen steadily over recent ye

147 Gastric bypass surgery can dramatically improve type 2 diabetes.

148 induced by cardiac arrest or cardiopulmonary bypass surgery, causes cell death in vulnerable hippocam

149 We conclude that in T2D, bypass surgery changes the postprandial response to a du

150 ter 10 years of follow-up, Roux-en-Y gastric bypass surgery, compared with nonsurgical medical manage

151 ume-outcome relationship for coronary artery bypass surgery, coronary angioplasty, carotid endarterec

152 rdial infarction, or angina, coronary artery bypass surgery, coronary angioplasty, or abnormal corona

153 Cardiopulmonary bypass surgery (CPB) is associated with a high incidence

154 Patients who have undergone bypass surgery do not produce such plaque but instead fo

155 Prophylactic IVC filters for gastric bypass surgery do not reduce the risk of pulmonary embol

156 25; P<0.001), and history of coronary artery bypass surgery (DTR=2.81; P<0.001).

157 %) of 355 patients underwent aortic or iliac bypass surgery during the follow-up period.

158 ained ventricular tachycardia not related to bypass surgery, EF, age, left ventricular conduction abn

159 eeve gastrectomy (VSG) and Roux-en-Y gastric bypass surgeries for obesity.

160 (Evaluation of Xience Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascular

161 risk factors for adverse outcomes after vein bypass surgery for limb salvage.

162 utaneous coronary intervention with coronary bypass surgery for multivessel coronary disease mandate

163 Bypass surgery for patients with multivessel disease and

164 orld, and to date there is no alternative to bypass surgery for severe coronary atherosclerosis.

165 US Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries [S

166 US Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries) t

167 were performed in 72 patients after gastric bypass surgery for treatment of morbid obesity.

168 l management plus standard Roux-en-Y gastric bypass surgery (gastric bypass).

169 Gastric bypass surgery (GBP) promotes early improvements in gluc

170 epression and death by suicide after gastric bypass surgery (GBP).

171 ate that patients who have undergone gastric bypass surgery (GBS) have a higher risk of inpatient car

172 tudy was to test the hypothesis that gastric bypass surgery (GBS) would favorably impact cardiac remo

173 8 kg/m(2)) human subjects undergoing gastric bypass surgery (GBS).

174 s who sought and underwent Roux-en-Y gastric bypass (surgery group), 417 patients who sought but did

175 2.6%, 3.0%; P<0.001) and need for emergency bypass surgery (groups 4 to 1: 0.4%, 0.5%, 1.6%, 5%; P<0

176 Patients undergoing gastric bypass surgery had a significantly lower age-related inc

177 control group, the group undergoing gastric bypass surgery had a significantly reduced incidence of

178 The group undergoing gastric bypass surgery had greater percentage of excess weight l

179 at black patients undergoing coronary artery bypass surgery had worse outcomes than white patients, e

180 ity and gender to the outcomes of peripheral bypass surgery has been controversial.

181 Off-pump coronary artery bypass surgery has been demonstrated to reduce morbidity

182 k of atrial fibrillation (AF) after coronary bypass surgery has been related to redox state, inflamma

183 Bypass surgery has been shown to prolong life in patient

184 cutaneous coronary interventions or coronary bypass surgery have been shown to improve outcomes.

185 ed, resulting in angioplasty in 6 (9.8%) and bypass surgery in 1 (1.6%).

186 study sample (74.5%) underwent laparoscopic bypass surgery in 2005.

187 n prophylactic angioplasty in 18 (6.2%), and bypass surgery in 8 (2.8%) before listing.

188 gina, myocardial infarction, angioplasty, or bypass surgery in a relative <50 years of age.

189 secondary to ischemic cardiomyopathy (prior bypass surgery in all cases; left ventricular ejection f

190 gives an overview of the need for emergency bypass surgery in both the large trial setting and the c

191 and harms of laparoscopic Roux-en-Y gastric bypass surgery in patients defined by weight class (over

192 The efficacy of bypass surgery in patients with ischemic cardiomyopathy

193 feasible alternative to open coronary artery bypass surgery in selected patient populations.

194 ars undergoing isolated AVR (with or without bypass surgery) in 1045 US hospitals during 1999-2001 fr

195 matory status, and was restored upon gastric bypass surgery-induced weight loss in morbid obesity.

196 Although gastric bypass surgery induces rapid weight loss and ameliorates

197 Vein graft failure following bypass surgery is a frequent and important clinical prob

198 Vein bypass surgery is an effective therapy for atherosclerot

199 Minimally invasive bypass surgery is an evolving technique.

200 within the 5 days preceding coronary artery bypass surgery is associated with a lower risk of postop

201 n graft failure within the first month after bypass surgery is largely because of thrombosis.

202 ion, and early revascularization with PCI or bypass surgery is now the preferred management strategy.

203 A decision for bypass surgery is often based on the durability of surgi

204 lihood of complications, and coronary artery bypass surgery is often required.

205 Gastric bypass surgery is protective against mortality even for

206 Early use of aspirin after coronary bypass surgery is safe and is associated with a reduced

207 Recent and ongoing progress will make bypass surgery largely obsolete within the next several

208 We hypothesized that gastric bypass surgery leads to a lower incidence of heart failu

209 Gastric bypass surgery leads to marked improvements in glucose t

210 eral artery disease includes lower extremity bypass surgery (LEB) and peripheral endovascular interve

211 ly by the stomach, weight loss after gastric bypass surgery may be accompanied by impaired ghrelin se

212 s who undergo laparoscopic Roux-en-Y gastric bypass surgery may be at increased risk for alcohol use

213 Coronary artery bypass surgery may be the preferred revascularization st

214 from gut reconstruction as seen with gastric bypass surgery most likely contributes to the superior e

215 tion (HCR) combines arterial coronary artery bypass surgery (most commonly minimally invasive) and pe

216 re defined as death, need for angioplasty or bypass surgery, myocardial infarction, and a >25% worsen

217 ceived either laparoscopic Roux-en-Y gastric bypass surgery (n = 100) or laparoscopic adjustable gast

218 trant (n = 3,806), diet (n = 458), and ileal bypass surgery (n = 838).

219 pass, aortobifemoral bypass, coronary artery bypass surgery, oesophagectomy, colectomy, pancreatectom

220 ormed in 185 patients during coronary artery bypass surgery of whom 13 had a history of paroxysmal AF

221 ly studied 5065 patients undergoing coronary bypass surgery, of whom 5022 survived the first 48 hours

222 ing evidence points to the effect of gastric-bypass surgery on body weight, including alteration of g

223 ness of on-pump and off-pump coronary artery bypass surgery on early clinical outcome in a consecutiv

224 Our results show that duodenal bypass surgery on obese, insulin-resistant Zucker fa/fa

225 essed the midterm effects of coronary-artery bypass surgery on the beating heart, this technique is b

226 amine the effect of off-pump coronary artery bypass surgery on the risk of postoperative acute kidney

227 s studies comparing off-pump coronary artery bypass surgery (OPCABG) to conventional techniques utili

228 f the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation,

229 knee arterial disease that limits the use of bypass surgery or balloon angioplasty.

230 gh-risk repeated sternotomy and conventional bypass surgery or catheter-based intervention, the circu

231 arterial disease and is usually treated with bypass surgery or endovascular revascularization.

232 otential viable alternative to open coronary bypass surgery or multivessel stenting.

233 ar stenoses who are potential candidates for bypass surgery or neuroendovascular treatment, for the e

234 uited in patients undergoing coronary artery bypass surgery or percutaneous coronary interventions an

235 status, need for concomitant coronary artery bypass surgery, or baseline LVM.

236 all myocardial infarction, emergent coronary bypass surgery, or clinically indicated target lesion re

237 nts of myocardial infarction, same-admission bypass surgery, or death.

238 events (myocardial infarction, angioplasty, bypass surgery, or IHD death) among those screened and n

239 coronary intervention (PCI), coronary artery bypass surgery, or valve surgery be referred to cardiac

240 tients with cardiogenic shock, with previous bypass surgery, or who received fibrinolysis, 2947 patie

241 ation ("should be done") for a preference of bypass surgery over percutaneous coronary intervention.

242 ton, Massachusetts, and involved 770 gastric bypass surgery patients between January 1, 2007, and Dec

243 The 25 804 gastric bypass surgery patients had on average lost 18.8 kg more

244 re is increasing evidence that after gastric bypass surgery, patients and animal models show a decrea

245 After coronary artery bypass surgery, patients have a high cumulative rate of

246 n patients with a history of coronary artery bypass surgery (PCI-CABG) is limited and the long-term e

247 CAO and hemodynamic cerebral ischemia, EC-IC bypass surgery plus medical therapy compared with medica

248 or operative mortality after coronary artery bypass surgery, race does not appear to be a significant

249 Coronary artery bypass surgery rates increased significantly with increa

250 or treating depression after coronary artery bypass surgery, relative to usual care.

251 In patients with prior gastrointestinal bypass surgery, renal allografts are also at risk of oxa

252 who underwent laparoscopic Roux-en-Y gastric bypass surgery reported a significant increase in the fr

253 INTERPRETATION: Roux-en-Y gastric bypass surgery resulted in substantial and durable bodyw

254 Gastric bypass surgery resulted in the selective reduction of th

255 tes are comparable to historic single vessel bypass surgery revascularization rates.

256 tes mellitus shortly after Roux-en-Y gastric bypass surgery (RYGB) and before there is major weight l

257 Roux-en-Y gastric bypass surgery (RYGB) results in remission of insulin re

258 ment for morbid obesity is Roux-en-Y gastric bypass surgery (RYGB), which results in rapid remission

259 Roux-en-Y gastric bypass surgery (RYGBP), the most commonly performed proc

260 Patients undergoing gastric bypass surgery seen at a private surgical practice from

261 Lastly, duodenal bypass surgery selectively altered the tissue concentrat

262 at Abs to PRT/H occur commonly after cardiac bypass surgery, share a number of serologic features wit

263 abetes remission following Roux-en-Y gastric bypass surgery, suggesting new therapeutic approaches ag

264 neurones were not reversed following gastric bypass surgery, suggesting that they may be due to diet,

265 Gastrointestinal bypass surgeries that result in rerouting and subsequent

266 s frequently relapse after Roux-en-Y gastric bypass surgery, the authors sought to assess whether SRI

267 mong the 7925 patients who underwent gastric bypass surgery, the mean (SD) age at surgery was 39.5 (1

268 is commonly performed before coronary artery bypass surgery, there has yet to be a study examining th

269 l glycemia excursions increase after gastric bypass surgery; this effect is even greater among patien

270 rdial biopsies were obtained during coronary bypass surgery to assess glucose transporter (GLUT4) dis

271 in 2059 patients undergoing coronary artery bypass surgery to assess the effect of haemoglobin conce

272 atients with type 2 diabetes, adding gastric bypass surgery to lifestyle and medical management was a

273 Potential benefits of adding gastric bypass surgery to the best lifestyle and medical managem

274 alence of IPF in subjects undergoing gastric bypass surgery, to identify biochemical variables associ

275 e ICU after multiple complications following bypass surgery, under anticoagulation after a recent aor

276 abase (1986-2003) with prior coronary artery bypass surgery undergoing cardiac catheterization who ha

277 chemic ventricular dysfunction scheduled for bypass surgery underwent preoperative dobutamine echocar

278 those undergoing and not undergoing gastric bypass surgery using HRs.

279 Gastric bypass surgery was associated with approximately one hal

280 ll associated with increased risk, and prior bypass surgery was associated with decreased risk.

281 Gastric bypass surgery was associated with improved long-term su

282 Minimally invasive direct coronary artery bypass surgery was developed to reduce chest trauma and

283 ntervention was performed in 59 percent, and bypass surgery was performed in 41 percent.

284 Coronary artery bypass surgery was performed in 44 cases because of comp

285 30 children immediately postcardiopulmonary bypass surgery was recruited.

286 , adjusted all-cause mortality after gastric bypass surgery was significantly lower for patients 35 t

287 Long-term total mortality after gastric bypass surgery was significantly reduced, particularly d

288 For laparoscopic gastric bypass surgery, we used empirical Bayes techniques to cr

289 from 39 patients undergoing coronary artery bypass surgery were evaluated for the absence of collate

290 itant cardiac operations except for coronary bypass surgery were excluded.

291 ortality and morbidity after coronary artery bypass surgery were higher among black patients than amo

292 egments from 19 patients undergoing coronary bypass surgery were incubated with or without cytokines

293 failure, myocardial infarction, or coronary bypass surgery were less likely to receive reperfusion t

294 to whites, blacks undergoing coronary artery bypass surgery were younger, yet had higher comorbiditie

295 se, followed by percutaneous intervention or bypass surgery where appropriate.

296 omes for patients undergoing primary gastric bypass surgery with those who had gastric bypass procedu

297 t studies comparing off-pump coronary artery bypass surgery with traditional on-pump coronary artery

298 ation (percutaneous coronary intervention or bypass surgery within 3 months) and non-early revascular

299 The effect of the use of coronary-artery bypass surgery without cardiopulmonary bypass and cardia

300 ended for all patients after coronary artery bypass surgery, yet little is known about the long-term